19 completed. 19 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 19 | Completed 19 |
Follow Eczema: new trials by email Literature Review of Eczema trials Research Report on Eczema
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effects of Abrocitinib in Subjects With Atopic Dermatitis With an Unsatisfactory Response After Treatment With Dupilumab Abrocitinib - Atopic Dermatitis | Phase 4 | Completed | Innovaderm Research Inc. | 24 | 2022-11-25 | 2025-03-28 |
| The Utility of Functionally Relevant Signature Genes in Assessing the Clinical Outcomes of Dupilumab Treatment Dupilumab Prefilled Syringe - Atopic Dermatitis, Eczema | Phase 4 | Completed | Jonathan A. Bernstein, MD | 12 | 2020-09-01 | 2023-02-08 |
| Steroid-reducing Effects of Crisaborole Crisaborole, Hydrocortisone Ointment, Triamcinolone ointment - Atopic Dermatitis, Eczema | Phase 4 | Completed | Johns Hopkins University | 24 | 2019-12-17 | 2024-07-19 |
| Response of Children With Atopic Dermatitis (Eczema) to Eucrisa Crisaborole - Atopic Dermatitis, Eczema | Phase 4 | Completed | Ann & Robert H Lurie Children's Hospital of Chicago | 30 | 2019-10-03 | 2022-07-19 |
| The Impact of Dupilumab on Quality of Life in Moderate to Severe Atopic Dermatitis Patients Dupilumab - Atopic Dermatitis, Atopic Dermatitis Eczema | Phase 4 | Completed | University of California, San Francisco | 34 | 2018-11-01 | 2024-01-09 |
| Immunogenetic Profiling of Dupilumab for the Treatment of Atopic Dermatitis Dupilumab - Atopic Dermatitis, Atopic Dermatitis Eczema | Phase 4 | Completed | University of California, San Francisco | 17 | 2018-10-22 | 2025-11-14 |
| Effect of Sublingual Immunotherapy in Patients With Atopic Dermatitis Mite extract sublingual immunotherapy (SLIT), Placebo - Atopic Dermatitis, Effects of Immunotherapy | Phase 4 | Completed | Casa Espirita Terra de Ismael | 91 | 2018-05-02 | 2020-08-26 |
| Efficacy and Tolerability of New Topical Formulations in Subjects With Atopic Dermatitis Investigational OTC Cream, Cosmetic Eczema Cream, 0.05% Desonide Cream - Dermatitis, Atopic, Eczema | Phase 4 | Completed | Procter & Gamble Beauty | 53 | 2016-03-01 | 2016-10-05 |
| Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection Retapamulin (Altabax) - Impetigo, Folliculitis | Phase 4 | Completed | The University of Texas Health Science Center, Houston | 38 | 2010-04-01 | 2016-02-17 |
| Bilateral Comparison Study of Elidel 1% and Hylatopic Plus Emollient Foam for the Treatment of Subjects With Atopic Dermatitis Elidel (pimecrolimus cream, 1%) Hylatopic Plus Emollient Foam (non-medicated device) - Eczema, Atopic Dermatitis | Phase 4 | Completed | Frankel, Amylynne, M.D. | 30 | 2010-03-01 | 2011-04-15 |
| A Study Evaluating the Efficacy of Fluocinonide Cream 0.1% (Vanos) in Subjects With Atopic Dermatitis Fluocinonide Cream 0.1% - Atopic Dermatitis | Phase 4 | Completed | Wake Forest University Health Sciences | 20 | 2009-03-01 | 2018-08-01 |
| Measuring Adherence to Topical Therapy in Children With Atopic Dermatitis and the Impact of a Return Visit tacrolimus ointment - Atopic Dermatitis | Phase 4 | Completed | Wake Forest University | 30 | 2008-04-01 | 2018-08-01 |
| Efficacy Study of Montelukast in Atopic Dermatitis Induced by Food Allergens Montelukast, Placebo - Atopic Dermatitis | Phase 4 | Completed | 1st Allergy & Clinical Research Center | 20 | 2008-03-01 | 2015-04-21 |
| Multicenter Clinical Study to Examine the Efficacy and Safety of Zarzenda in Patients With Hand Eczema Zarzenda - Hand Eczema | Phase 4 | Completed | Bayer | 40 | 2007-06-01 | 2023-10-31 |
| Epiceram Versus Elidel for Treatment of Mild to Moderate Atopic Dermatitis Elidel(R) (pimecrolimus 1%), EpiCeram(R) -ceramide based barrier repair cream - Atopic Dermatitis | Phase 4 | Completed | Ceragenix Pharmaceuticals | 35 | 2007-04-01 | 2008-02-06 |
| Epiceramâ„¢ Device Versus Mid-Strength Topical Steroid (Fluticasone Propionate 0.05%) for Treatment of Atopic Dermatitis Epiceram(r), Fluticasone Propionate 0.05% - Atopic Dermatitis | Phase 4 | Completed | Ceragenix Pharmaceuticals | 121 | 2006-12-01 | 2008-02-15 |
| Reconstitution With Pimecrolimus Cream 1% of Steroid-damaged Skin in Adults With Atopic Dermatitis Pimecrolimus cream 1% - Atopic Dermatitis | Phase 4 | Completed | Novartis | 41 | 2006-03-01 | 2017-02-24 |
| Efficacy and Safety of Pimecrolimus Cream 1% in Patients ≥ 3 Months of Age With Mild or Moderate Atopic Dermatitis Pimecrolimus Cream 1% - Atopic Dermatitis | Phase 4 | Completed | Novartis | 2004-12-01 | 2008-02-15 | |
| Assessment of Pruritus Improvement With Pimecrolimus Treatment on the Areas Affected by Mild-to-moderate AD, in Patients 2- to 11- Year-old Pimecrolimus - Atopic Dermatitis | Phase 4 | Completed | Novartis Pharmaceuticals | 117 | 2004-12-01 | 2016-11-18 |
Dermatitis, Atopic (18) · Dermatitis (2) · Pruritus (2) · Folliculitis (1) · Impetigo (1) · Infections (1)
Skin Diseases (19) · Skin Diseases, Eczematous (19) · Skin and Connective Tissue Diseases (19) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (18) · Genetic Diseases, Inborn (18) · Hypersensitivity (18) · Hypersensitivity, Immediate (18) · Immune System Diseases (18) · Skin Diseases, Genetic (18) · Dermatitis (17) · Pathological Conditions, Signs and Symptoms (2) · Signs and Symptoms (2) · Skin Manifestations (2) · Bacterial Infections (1) · Bacterial Infections and Mycoses (1)
dupilumab (3) · pimecrolimus (3) · crisaborole (2) · Fluocinonide (1) · Petrolatum (1) · Sublingual Immunotherapy (1) · abrocitinib (1) · montelukast (1) · retapamulin (1)
Ceragenix Pharmaceuticals (2) · Novartis (2) · University of California, San Francisco (2) · 1st Allergy & Clinical Research Center (1) · Ann & Robert H Lurie Children's Hospital of Chicago (1) · Bayer (1) · Casa Espirita Terra de Ismael (1) · Frankel, Amylynne, M.D. (1) · Innovaderm Research Inc. (1) · Johns Hopkins University (1) · Jonathan A. Bernstein, MD (1) · Novartis Pharmaceuticals (1) · Procter & Gamble Beauty (1) · The University of Texas Health Science Center, Houston (1) · Wake Forest University (1)
United States (13) · Germany (2) · Brazil (1) · Canada (1) · Philippines (1) · Spain (1)
Adelaide A Hebert, M.D. (1) · Adnan Nasir, MD, PhD (1) · Anna Fishbein, MD (1) · Anna Grossberg, MD (1) · Eric Simpson, MD (1) · Isaac R Melamed, MD (1) · Jeffrey Sugarman, MD (1) · Jonathan Bernstein (1) · Karla L Arruda, PhD (1) · Lawrence Parrish, MD (1) · Robert Bissonnette, MD (1)